← All trials
NCT05455294
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 18, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2026
- First posted
- Jul 13, 2022
- Last posted
- Jul 26, 2022
- Enrollment
- 36
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- AbbVieCollaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.